share_log

GRAIL Announces The First Patient Has Been Tested For Eligibility With Its Non-Small Cell Lung Cancer CtDNA Assay In The TROPION-Lung12 Phase 3 Study, Sponsored By AstraZeneca In Collaboration With Daiichi Sankyo

Benzinga ·  16:02
GRAIL Announces The First Patient Has Been Tested For Eligibility With Its Non-Small Cell Lung Cancer CtDNA Assay In The TROPION-Lung12 Phase 3 Study, Sponsored By AstraZeneca In Collaboration With Daiichi Sankyo
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment